Back to fellows
Profile Background
profile

Professor
Jean Nachega

Related fellows

Dr Moses Egesa

Associate Professor Yaya Kassogue

Associate professor in Genetic and Molecular Pathology

View
Dr Moses Egesa

Dr Zivai Nenguke

Project Director

View
Dr Moses Egesa

Professor Andre Pascal Kengne

Director, Non-Communicable Diseases Research Unit

View
Show more

Project Title

A Multi-Site Double-Blind Placebo Controlled Randomised Clinical Trial to Prevent Immune Reconstitution Inflammatory Syndrome with Non- Steroid Anti-Inflammatory Drugs

EDCTP Project

TA.2008.40200.021

EDCTP Program

EDCTP1

EDCTP Project Call

Senior Fellowship (SF)

Project Objectives

Evaluate the impact of NSAIDs compared to placebo on preventing TB-IRIS in a TB-HIV infected South African Adults Evaluate the impact of NSAIDs compared to placebo on CD4+ T-cell count recovery following initiation of ART in TB-HIV infected South African Adults Evaluate the impact of NSAIDs compared to placebo on HIV-1 RNA response following initiation of ART in TB-HIV infected South African Adults Evaluate the impact of NSAIDs compared to placebo on adherence of both TB and HIV medication following initiation of ART in TB-HIV infected South African Adults Assess the impact of NSAIDs compared to placebo on quality of life

Study Design

Phase II: Randomised placebo control trial for prevention of TB-IRIS with non-steroidal ant-inflammatory drugs on TB patients on HAART

Host Organisation

Department Institution Country
Stellenbosch University (SU) South Africa

Results & Outcomes

Enrolment into the study started on 1 April 2014 . A GMP manufacturing facility for preparation of the double-blind (double-dummy capsules) formulation of Meloxicam (Mobic®) and placebo has been finalized; this work has been managed by the University of the Western Cape (Dr R Bapoo) under supervision of the Division of Pharmacology, Stellenbosch University (Professor Rosenkranz, co-investigator on this project and head of Division of Clinical Pharmacology at Stellenbosch University).